Genetic variants in PPP3R1 and MAPT have been shown to be associated with cerebrospinal fluid p-tau levels and rate of decline in Alzheimer's disease patients in three independent samples [147, 149]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.